Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), focused on cancer treatments, announced its management team's participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON), focused on cancer treatments, announced its management team's participation in two upcoming investor conferences. The events include the Piper Sandler's 34th Annual Healthcare Conference on November 29, 2022, at 11:30 a.m. ET, and Evercore ISI's 5th Annual HealthCONx on December 1, 2022, at 1 p.m. ET. Investors can access the fireside chats live and view replays on the company's website. Kronos Bio is advancing two investigational compounds: a CDK9 inhibitor for MYC-amplified solid tumors and lanraplenib for FLT3-mutated acute myeloid leukemia.
Details
News Market Reaction – KRON
The recorded move for KRON in the trading session of this news was -1.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
- Piper Sandler’s 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 11:30 a.m. ET; and
- Evercore ISI’s 5th Annual HealthCONx on Thursday, December 1, 2022, at 1 p.m. ET.
The fireside chats will be available on the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcasts will be archived and available for one month following each event.
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor, KB-0742, as a treatment for MYC-amplified solid tumors, and lanraplenib, a next-generation SYK inhibitor, for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company’s scientific focus is on developing medicines that target the dysregulated transcription that is the hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Company contact:
Marni Kottle
Kronos Bio
650-900-3450
mkottle@kronosbio.com
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com
Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.